3,366 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by BOK Financial Private Wealth Inc.

Key Points

• BOK Financial Private Wealth purchased 3,366 Thermo Fisher Scientific shares valued at approximately $1.69 million. Institutional investors and hedge funds collectively own 89.23% of the company.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in EPS and $11.99 billion in revenue, with revenue up 10.5% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $619.41.
• The stock opened at $614.32 and is up 4.3%, while the company declared a quarterly dividend of $0.47 per share, representing a 0.3% yield.

BOK Financial Private Wealth Inc. purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 3,366 shares of the medical research company's stock, valued at approximately $1,689,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. North Dakota State Investment Board bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $7,505,000. BlackRock Inc. bought a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $15,501,867,000. Hudson Value Partners LLC lifted its holdings in Thermo Fisher Scientific by 24.9% in the second quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company's stock valued at $8,349,000 after buying an additional 3,317 shares during the period. Boston Trust Walden Corp boosted its position in shares of Thermo Fisher Scientific by 9.7% during the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company's stock valued at $25,480,000 after purchasing an additional 3,873 shares in the last quarter. Finally, Xponance LLC grew its position in shares of Thermo Fisher Scientific by 8.1% during the 4th quarter. Xponance LLC now owns 59,295 shares of the medical research company's stock worth $34,358,000 after buying an additional 4,436 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on the company. Wolfe Research started coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 target price for the company. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a research note on Friday, April 24th. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Piper Sandler lifted their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a report on Monday, July 27th. Finally, Morgan Stanley boosted their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $619.41.

Thermo Fisher Scientific Trading Up 4.3%

NYSE TMO opened at $614.32 on Thursday. The company has a market capitalization of $227.14 billion, a price-to-earnings ratio of 33.05, a PEG ratio of 2.40 and a beta of 0.85. The stock's 50-day simple moving average is $536.26 and its two-hundred day simple moving average is $508.51. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. During the same period last year, the business earned $4.28 earnings per share. The business's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 5,850 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the completion of the transaction, the vice president directly owned 14,784 shares in the company, valued at approximately $8,574,720. The trade was a 28.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 52,053 shares of company stock worth $30,643,589 over the last quarter. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source